Annals of Oncology
@Annals_Oncology
Followers
49K
Following
552
Media
738
Statuses
4K
Medical oncology journal with a specific interest on targeted agents, immune therapies, personalised medicine, molecular pathology, bioinformatics, and more.
Joined June 2009
Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail or subscribe to our RSS
12
10
52
Congratulations to our Editor-in-chief @FAndreMD for receiving today at #SABCS21 the @AACR Outstanding Investigator Award for Breast Cancer Research 👏👏👏. @SABCSSanAntonio @BCRFcure @GustaveRoussy @myESMO
11
21
202
In Annals of Oncology, results from the German 🇩🇪 #PrecisionMedicine 🧬🎯💊 NCT/DKTK MASTER trial inform on the association of cancer perdisposing genes and rare cancer.
0
61
163
Artificial intelligence as a tool to identify predictive biomarker in immuno-oncology: .this systematic review by @PrelajArsela and coll. in Annals of Oncology encompasses genomics, radiomics, pathomics, real-world and multimodal data
3
75
173
Cancer of unknown primary (CUP) has a low prevalence but a high mortality rate. In Annals of Oncology, the @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of CUP: .
0
54
145
How to tailor adjuvant chemotherapy in HR+/HER2- early #BreastCancer ? Do not miss this recent manuscript in Annals of Oncology that provides input based on the results of TAILOR-x, MINDACT and Rx-PONDER #bcsm @JulesBordet @KalinskyKevin @DrEricWiner
2
67
141
With #ESMOBreast20 just around the corner, Annals of Oncology has prepared a collection of most read #BreastCancer articles. Free access using this link: #bcsm @myESMO
0
73
132
Now available #OpenAccess in Annals of Oncology, recommendations by the @myESMO Precision Medicine Working Group for the use of NGS for patients with advanced cancer in 2024. 🧬Expanding indications.🧬CUP & tissue-agnostic situations.🧬Best practice.
0
62
132
Abemaciclib + endocrine therapy for early breast cancer was approved by @FDAOncology based on the monarchE study. Results of the the primary outcome analysis presented at the #ESMOVirtualPlenary are available #openaccess in @Annals_Oncology #bcsm
1
67
125
In Annals of Oncology, the @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of pancreatic cancer 👇.@icl_lorraine @DucreuxMichel @ArndtVogel @EileenMOReilly @DrAngelaLamarca.
0
55
125
New article in press: Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. @GroupeUnicancer @icl_lorraine .
1
48
122
Now available in Annals of Oncology, the @myESMO Clinical Practice Guideline for the diagnosis and management of venous thromboembolism in patients with cancer
0
49
110
Letter to the Editor in Annals of Oncology reporting the successful treatment of a patient with cancer and severe pulmonary manifestations of #COVID19 with Tocilizumab, anti-IL6 receptor moAb used for treating CRS seen with CAR-Ts @MichotJM @GustaveRoussy
2
69
108
📣Just out in Annals of Oncology, the @myESMO Clinical Practice Guidelines for fertility preservation and post-treatment pregnancies in post-pubertal patients with cancer @matteolambe @fedrophd @IDemeestere
1
66
97
Invasive lobular carcinoma (ILC) represents 15% of breast cancers & carries distinct pathological & clinical characteristics. This review in Annals of Oncology highlights diagnostic & treatment strategies for ILC. @VanBaelenKaren @ChristineDesme2 #bcsm.
2
44
102
Tumor mutational burden (TMB) has emerged as a tissue-agnostic predictive biomarker for immunotherapy. Empirical variability exists across panel assays. The TMB Consortium investigated factors contributing to variability in this #OpenAccess paper
2
46
97
This review published in the September issue of Annals of Oncology provides an update on the use of PARP inhibitors in ovarian cancer #gyncsm
0
47
97
The new impact factor has been released and we are happy to see that the Annals of Oncology IF has increased to an all-time high of 18.274! 📈
1
18
99
On June 16th 2020, @FDAOncology granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with tumor mutational burden-high 🧬(TMB-H). In Annals of Oncology a pro and con editorial debate
0
40
92
Today we’re pleased to announce the launch of our brand new website! The January 2020 edition of Annals of Oncology has also arrived. All articles in the issue are free to read @myesmo
2
32
90
Adrenocortical carcinoma (ACC) and malignant phaeochromocytoma are rare malignancies that require multidisciplinary management. You can find the ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up in Annals of Oncology: @myESMO
0
47
88
New article in press: Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study.
0
28
91
TMB-H is approved as a histology-agnostic biomarker for therapy with an immune checkpoint inhibitor. This study published #openaccess in Annals of Oncology shows that context matters: response is not universal in all tumor types @MDAndersonNews @NKI_nl
2
33
86
In Annals of Oncology, a report on the STING (NCT04932525) study in which patients with advanced cancer had molecular profiling using a ctDNA sequencing assay 🩸🧬 and were assigned matched therapy 💊 as per a molecular tumor board. @GustaveRoussy @ArBayle.
0
40
85
Pembrolizumab in early TNBC was recently evaluated by @FDAOncology after the initial results of KEYNOTE-522. This review in the March 2021 issue by @AliceFranzoi and coll. provides an overview on IO in early breast cancer #bcsm @JulesBordet @institut_curie
1
38
84
NTRK gene fusions 🧬 are oncogenic and highly actionable 💊. Just out and #openaccess in Annals of Oncology: expert recommendations from the World Sarcoma Network for the diagnosis and management of TRK fusion sarcomas @DrSarcoma @jeanyvesblay
0
41
84
Cancer of unknown primary (CUP) is defined as metastatic cancer for which identification of the primary site was not possible and accounts for 2% to 5% of cancer cases. Results of a phase 2 study of Nivolumab in CUP (including biomarker analyses) 👇.
1
38
86
Now in press 📰 in Annals of Oncology: the consensus 🤝 guidelines for the treatment of early breast cancer from the 17th St Gallen International Breast Cancer Consensus Conference in 2021 #bcsm .@DrHBurstein @curijoey @DrEricWiner @MichaelGnant.
0
49
83
Following the presentation at the @myESMO Virtual Plenary, the OS analyses from the OlympiA phase III trial of adjuvant olaparib in patients with gBRCA1/2 & high risk, early breast cancer are now available #OpenAccess in Annals of Oncology #bcsm
0
37
83
📢New review in press: Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy @AndresC27622123 .
0
31
81
New article in press: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. @jeanyvesblay.
1
30
79
ctDNA 🩸🧬🧪 analyses as a predictive biomarker in early-stage triple-negative breast cancer: the association of ctDNA dynamics with RCB during neoadjuvant therapy in the TBCRC 030 clinical trial @DFCI_BreastOnc @broadinstitute #bcsm
0
30
81
The @myESMO ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer is now available in @Annals_Oncology.👉 #bcsm @ALEDIGNUS12 @FAndreMD.
0
34
76
In Annals of Oncology, review discussing: .🐉Resistance to targeted therapies.🐉Mixed responses on treatment.🐉Tumor subclones.🐉Means of monitoring .🐉Tailored N-of-1 combos . @jacobadashek @VivekSubbiah @BenWestphalen @ANaingMD @Dr_R_Kurzrock
0
41
72
Immune-related adverse events (irAEs) can occur more than 1 year after starting anti-PD1 therapy. This manuscript describes the characteristics and course of delayed irAEs in a series of 118 patients treated for melanoma @ProfGLongMIA @sandrineaspesla
0
33
75
The use of NGS on DNA🧬 from tissue or liquid biopsies is now well established in the management of patients with cancer. In this Letter to the Editor, @ArBayle and coll. present the data from cases tested with both modalities in PRISM 🇫🇷.
1
34
74
Early detection could improve cure rates, mainly in cancers without screening modalities. 📢 Just out in Annals of Oncology : Clinical validation of a targeted methylation-based multi-cancer early.detection test 🩸🧬 using an independent validation set
1
28
71
In this new review in Annals of Oncology, @FCortiula and coll. discuss immunotherapy in unresectable stage III NSCLC:.✅State of the art and rationale.✅Treatment synergisms.✅Ongoing clinical trials.✅Unmet needs and future biomarkers.#LCSM .
0
32
72
In Annals of Oncology, the @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of biliary tract cancer @ArndtVogel @DucreuxMichel.
0
36
69
Just out in Annals of Oncology, results of Pooled analyses from four 1L Nivolumab + Ipilimumab studies in NSCLC including landmark analyses of OS by response status at 6 months and by tumor-burden reduction #LCSM
0
30
71
With the increase 📈 in the number of approved targeted therapies 🎯💊 , @VPrasadMDMPH and coll. evaluated the uptake and response to genome-targeted oncology drugs in the US using mortality data from @AmericanCancer and the @FDAOncology labels
0
31
73
In Press in Annals of Oncology: after correction for clonal hematopoiesis, liquid biopsies using ctDNA dynamics 🧪🧬 post-resection of esophageal adenocarcinoma provides prognostic information that could potentially inform adapted therapeutic strategies
1
25
68
Both somatic and germline genomic alterations 🧬 can guide management in solid tumors 🎯💊. This original article available #openaccess shows that 10.5% of pathogenic germline variants in clinically relevant genes can be missed by tumor-only sequencing.
1
33
69
Now available in Annals of Oncology, the @myESMO clinical practice guidelines for the diagnosis, treatment and follow-up of anal cancer, a rare disease accounting for less than 1% of all cancers
0
30
72
A HLA-corrected TMB algorithm (TMB in combination with loss of heterozygosity of HLA) to better select patients who may benefit from immunotherapy. Read this #EditorsChoice #openaccess paper in Annals of Oncology #LCSM #ImmunoOnc
1
32
69
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up @myESMO @EANOassociation.
0
37
67
NRG1 fusions are rare oncogenic genomic alterations 🧬 with potentially effective therapeutic options 💊. Learn more in the paper published #openaccess in Annals of Oncology #lcsm @StephenVLiu @alexdrilon @CadranelJ.
1
27
65
Sacituzumab Govitecan (SG), an anti-Trop2 ADC, is approved by the @FDAOncology for metastatic TNBC. Just out #openaccess in Annals of Oncology: encouraging activity for SG in patients with pretreated HR+/HER2- MBC #bcsm @ABhealer108 @stolaney1
2
33
66
Just out and #openaccess in Annals of Oncology: Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer #lcsm @StephenVLiu @LeciaSequist
0
31
66
Liquid biopsies using ctDNA 🩸🧪🧬as a predictor of outcome during and after neoadjuvant chemotherapy for early #BreastCancer : .❌on-treatment ctDNA+ was associated with residual disease .✅post-therapy ctDNA- was associated with a better outcome .#bcsm
1
37
63
The quest for a pan-cancer predictive biomarker of ICB benefit beyond TMB-H continues. @barechey and coll. performed a pan-cancer gene expression meta-analysis identifying PredictIO, a gene expression signature with consistent predictive potential. ➡️
2
21
59
❓Can PARP inhibition improve overall survival (OS) in HRD+ newly diagnosed advanced ovarian cancer?.👉The prespecified final OS analysis from the PAOLA-1/ENGOT-ov25 study testing olaparib + bevacizumab 1L maintenance is reported in Annals of Oncology
0
22
63
Nivolumab + ipilimumab improved OS vs chemo as 1st line treatment for unresectable malignant pleural mesothelioma in the CheckMate 743 ph 3 study. Updated data with 3-year follow-up have been published #openaccess in Annals of Oncology.@peters_solange.
2
19
66
In the PROMISE-meso randomised phase III trial now published in Annals of Oncology, Pembrolizumab does not improve PFS nor OS over single-agent chemotherapy in relapsed malignant pleural mesothelioma @DrSanjayPopat @peters_solange.
2
34
65
The Avelumab/Axitinib combo was approved for the treatment of metastatic renal cell carcinoma in the 1st line setting following the results of JAVELIN Renal 101. Updated efficacy data are reported in Annals of Oncology @DrChoueiri @AlbigesL #KidneyCancer.
0
41
63
#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: #LCSM @GLambertiMD @meyersonlab
0
36
63
We are pleased to reveal Annals of Oncology’s new Impact Factor is 13.926! We’ve created a collection of highly cited articles which contributed to the rise to explore online @myESMO
3
18
63
📢New in press: Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.@laura_huppert @hoperugo @DrLauraEsserman @ISPY2trial
2
23
61
Can acetaminophen, a widely used analgesic, impact the efficacy of immune checkpoint inhibitors (ICIs)?.@AItalianoMD and coll. studied the correlation of acetaminophen exposure with clinical outcome in 3 independent cohorts of patients treated with ICIs.
0
26
62
The pivotal study of Tucatinib (HER2CLIMB) in patients with HER2+ metastatic breast cancer allowed the inclusion of patients with untreated and progressive brain metastases. The final overall survival analysis is available👇. @curijoey @DrEricWiner #bcsm.
1
22
61
The @FDAOncology approved Dabrafenib + Trametinib in anaplastic thyroid cancer with a BRAF V600E mutation based on results from the phase 2 ROAR "basket" trial. Updated results including long-term survival are now available #openaccess .👇.@VivekSubbiah
0
28
61
❓Can single-agent or dual immunotherapy improve outcomes compared to the EXTREME regimen (platinum-based chemo + cetuximab) as 1st-line treatment for R/M HNSCC?.➡️Results of the KESTREL randomized Ph3 trial are available #OpenAccess in Annals of Oncology.
0
19
57
The IMpassion130 trial of atezolizumab + nab-paclitaxel in metastatic TNBC led to the regulatory approval of the first immunotherapy in #BreastCancer . PROs analyses from the phase III study now published in the May 2020 issue of Annals of Oncology #bcsm.
0
27
58
Many presentations at #ESMO21 cited the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Find more on ESCAT and #PrecisionMedicine 🧬🎯💊in these @Annals_Oncology resources:.
0
23
59
📢New @myESMO guidelines in press - Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.@ProfGLongMIA @beckilee @TeresaSAmaral.@OmidHamidMD @angelesclinic @matguc.@DoniaMarco .
1
25
61
Do not miss this #EditorsChoice paper in the November 2020 issue of Annals of Oncology - Recommendations for the use of next-generation sequencing (NGS) 🧬 for patients with metastatic cancers: a report from the @myESMO Precision Medicine Working Group
1
26
59
Post-operative chemoradiotherapy in the US and perioperative chemotherapy in Europe have been the standards for the treatment of gastric cancer. The CRITICS study published in Annals of Oncology randomly allocated patients to one of both strategies:
1
25
60
Just out in Annals of Oncology 📣, does androgen deprivation therapy (ADT) 💊 have a protective effect against infection with #COVID19 🦠? Data from the Veneto region 🇮🇹 and the biological rationale behind this hypothesis in this free access manuscript:
1
32
58
In Annals of Oncology, genomic characterization 🧬of HR+ breast cancer in very young women enrolled in SOFT shed light on unfavourable prognostic features potentially informing future therapeutic strategies .@LoiSher @etop_ibcsg #bcsm.
0
36
57
RET fusions are rare but highly actionable genomic 🧬 alterations in NSCLC & other tumor types. In Annals of Oncology, @GriesingerFrank and coll. report an updated analysis on patients with RET fusion+ NSCLC from the ARROW multi-cohort phase I/II study .
0
21
57
New article in press: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. @DrChoueiri @brian_rini @motzermd
1
16
56
Trastuzumab Deruxtecan was approved for the treatment of HER2+ MBC after 1 prior anti-HER2-based regimen following the results of DB03. In Annals of Oncology, @curijoey and colleagues report on PROs and hospitalization data from the phase 3 clinical trial.
1
20
57
In this new article in Annals of Oncology, @CharlesSwanton at al. review and discuss results from three genotype matched platform trials, drawing a roadmap for a future precision medicine strategy 🧬🎯💊 .
1
19
56
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the @myESMO Precision Medicine Working Group 🧬🎯 @demattosarruda
0
30
59
Novel anti-HER2 ADCs demonstrated compelling activity with an objective response rate of 37% across a large spectrum of tumor types with HER2 expression. This article in Annals of Oncology reports on HER2 status in different cancers including breast & GEJ.
1
16
58
Randomized clinical trial designs are sometimes not feasible. This review article in Annals of Oncology discusses the concept of external control arms as a way to circumvent this caveat. @pmishrakalyani @DrJuliaBeaver @realrickpazdur.
1
22
55
New article in press: A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases. @FAndreMD @curijoey @Prof_Nadia_H .
1
21
56
CAR-T cells targeting solid cancers have had limited success so far for multiple reasons, including their poor long-term persistence and proliferation. This review discusses early-phenotype CAR-Ts as a strategy to overcome this caveat @PeterMacCC
0
20
54
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma #melsm #EditorsChoice @myesmo
0
30
55
How to manage advanced #BreastCancer in 2020: discover the 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) #bcsm .@ESOncology @myESMO.
2
30
51
Could the gut microbiome🦠 be linked to the outcome of treatment with neoadjuvant chemo-radiotherapy 💉☢️ in rectal cancer ? You can find out more in this #openaccess paper in Annals of Oncology: @PaoloNuciforo @rdienstmann @TaberneroJosep #CRCSM.
0
40
53
The intestinal microbiome 🦠 is associated with response to immune checkpoint inhibitors in patients with cancer. The FIH MET4-IO study investigated MET4, an orally-delivered 30-species microbial consortium, with ICIs as a replacement to fecal microbiota.
0
31
54
#OpenAccess in Annals of Oncology, results of the ATALANTE-1 RCT investigating OSE2101, a vaccine inducing cytotoxic T lymphocytes against 5 tumor-associated antigens (HER-2, CEA, MAGE 2, MAGE 3 and p53) in HLA-A2+ NSCLC 🫁 after failure of an ICI #lcsm
1
22
51
With immune checkpoint inhibitors & targeted therapies approved in the adjuvant setting of stage III melanoma, the neoadjuvant approach offers several advantages. Just out 👇, survival updates of neoadjuvant IPI + NIVO in the OpACIN & OpACIN-neo trials
1
18
54
In his talk on priorities in #BreastCancer in the next 10 years at #ESMOBreast20 , Annals of Oncology EiC @FAndreMD discusses the promise of early detection of cancer using liquid biopsies. The CCGA & @GrailBio landmark paper is available #openaccess #bcsm
0
17
52
New article in press: Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.
1
13
53
Dr Romano from @GustaveRoussy presents at #ESMO20 the classification of genomic alterations from MOSCATO & MATCHR using @myESMO ESCAT. In Annals of Oncology, the recommendations of the @myesmo PMWG for the use of NGS for patients with metastatic cancers
3
30
51
Presented by @RebeccaDSing at #ESMOBreast24 w/ simultaneous publication in Annals of Oncology 1st results of Impassion132 showing no benefit of adding #atezoliyumab to 1st line CT in pts w/ advanced #TNBC relapsing <12months. #AnnOnc #BreastCancer
0
23
54
Just out in Annals of Oncology, the @myESMO recommendations on the use of ctDNA assays 💉🩸 🧬 for patients with cancer: from technical considerations to potential clinical indications including evidence for clinical utility.@jpascualmd .#PrecisionMedicine
0
26
53
Just out📣 in Annals of Oncology, the @myESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Localised Colon Cancer #crcsm @TaberneroJosep.
0
33
55